A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs […]
Prevalence and timing of authorized generics in the US market Read Post »
A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends Read Post »
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status
In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of
A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out
In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,”
DrugChatter recently launched as an experimental AI chat-based business intelligence tool. Here’s some of the more interesting questions it’s been
Get fresh news and insights, drug patent expirations & more…
